1693P CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
No Thumbnail Available
Authors
Albiges,L.
Powles,T. B.
Sharma,A.
Venugopal,B.
Bedke,J.
Borkowetz,A.
Gravis,G.
Ozdemir,B. C.
Schnabel,M. J.
Dutailly,P.
Contact
Check for full-text access
Issue Date
2024
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background: We report final data from CaboPoint, a prospective study of second-line (2L) cabozantinib in aRCC after first-line (1L) standard of care CPI-based therapy.
Description
Citation
Publisher
License
Journal
Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO
Volume
Issue
13-17